Patents Examined by Prema Mertz
  • Methods of using biomarkers for predicting the outcome of an immunotherapy against cancer
    Patent number: 8669063
    Abstract: The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: March 11, 2014
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Harpreet Singh, Andrea Mahr, Jens Fritsche
  • Humanized anti-IL-18 antibodies
    Patent number: 8637018
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: January 28, 2014
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • Nucleic acid encoding IL-7 receptor alpha antibody
    Patent number: 8637273
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: January 28, 2014
    Assignee: Rinat Neuroscience Corp.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • Anti-IL-6 antibodies
    Patent number: 8623362
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: January 7, 2014
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Modified human thymic stromal lymphopoietin
    Patent number: 8598318
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: December 3, 2013
    Assignee: Amgen Inc.
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Method for treating psoriasis by administering an antibody to interleukin-6 receptor
    Patent number: 8597644
    Abstract: A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: December 3, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroaki Ito, Kazuyuki Yoshizaki, Norihiro Nishimoto, Tadamitsu Kishimoto, Shin Shimaoka, Hidetomo Kitamura, Masamichi Sugimoto, Kenichi Akamatsu
  • Subcutaneously administered anti-IL-6 receptor antibody
    Patent number: 8580264
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 12, 2013
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Xiaoping Zhang, Min Bao, Angelika M. Jahreis, Kimio Terao
  • Treatment of cancers with A-8R peptide
    Patent number: 8575087
    Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: November 5, 2013
    Assignee: The University of Toledo
    Inventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
  • Anti-IL-23 antibodies
    Patent number: 8574579
    Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: November 5, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Sweet Raymond
  • Method of treating pulmonary disease by administering an antibody to G-CSF receptor
    Patent number: 8574572
    Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: November 5, 2013
    Assignee: CSL Limited
    Inventors: David Eric Crump, Andrew Donald Nash
  • Method of treating rheumatoid arthritis with an anti-IL-6R antibody
    Patent number: 8568721
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: October 29, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Method of reducing pruritis using IL-31 monoclonal antibodies
    Patent number: 8568723
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 29, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Biomarkers of tumor pharmacodynamic response
    Patent number: 8563254
    Abstract: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the case of cancers characterized by high levels of IL-8.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: October 22, 2013
    Assignee: Novartis AG
    Inventors: Michaela Bowden, Alan Buckler, Chantale T. Guy
  • Method of treating psoriatic arthritis with an IL-6 receptor antibody
    Patent number: 8562990
    Abstract: A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 22, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroaki Ito, Kazuyuki Yoshizaki, Norihiro Nishimoto, Tadamitsu Kishimoto, Shin Shimaoka, Hidetomo Kitamura, Masamichi Sugimoto, Kenichi Akamatsu
  • Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
    Patent number: 8557239
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 15, 2013
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Tom C. Harris, Martin Kaul, Parvez M. Mulani, Peter Noertersheuser, Martin M. Okun
  • Methods for treating IL-1? related diseases by administering an anti-IL-1? antibody
    Patent number: 8545846
    Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: October 1, 2013
    Assignee: XOMA Technology, Ltd.
    Inventors: Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer
  • IL-11 muteins
    Patent number: 8540977
    Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: September 24, 2013
    Assignee: CSL Limited
    Inventor: Manuel Baca
  • WDRPUH epitope peptides and vaccines containing the same
    Patent number: 8541546
    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: September 24, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Antibodies to interleukin-6
    Patent number: 8536308
    Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: September 17, 2013
    Assignee: Merck Patent GmbH
    Inventors: Jeffrey Way, Yuan Liu
  • Peptides for active anti-cytokine immunization
    Patent number: 8529881
    Abstract: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: September 10, 2013
    Assignee: Vaxconsulting
    Inventor: Jean-Francois Zagury